42 Results

People

  1. Hyman
    Hyman
  2. Drilon
    Drilon
  3. Solit
    Solit
  4. Berger
    Berger
  5. Schram
    Schram
  6. Iasonos
    Iasonos
  7. Ladanyi
    Ladanyi
  8. Zehir
    Zehir
  9. Diamond
    Diamond
  10. Schultz
    Schultz

Groups

  1. Department of Medicine (42)
  2. Early Drug Development Service (42)
  3. Solid Tumor Oncology Division (42)
  4. Human Oncology and Pathogenesis Program (25)
  5. GSK Faculty (24)
  6. Tow Center for Developmental Oncology (TCDO) (20)
  7. Epidemiology and Biostatistics (17)
  8. Gynecologic Medicine Service (17)
  9. Breast Medicine Service (14)
  10. Thoracic Oncology (14)
  1. "female"
  2. "David Hyman"
Formats
  1. Journal Article (40)
  2. Research Letter (2)
Groups
  1. Department of Medicine (42)
  2. Early Drug Development Service (42)
  3. Solid Tumor Oncology Division (42)
  4. Human Oncology and Pathogenesis Program (25)
  5. GSK Faculty (24)
  6. Tow Center for Developmental Oncology (TCDO) (20)

More Groups

People
  1. David Hyman (42)
  2. Marc Ladanyi (13)
  3. Alexander Drilon (12)
  4. Ahmet Zehir (10)
  5. Michael Berger (10)
  6. David Solit (9)

More People

Years
  1. 2024 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (9)
  5. 2019 (12)
  6. 2018 (7)

More Years

Publications
  1. JCO Precision Oncology (6)
  2. Cancer Discovery (4)
  3. Gynecologic Oncology (4)
  4. Clinical Cancer Research (3)
  5. Nature (3)
  6. Investigational New Drugs (2)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (6)
  4. Elsevier Inc. (4)
  5. Springer (3)
  6. American Medical Association (2)

More Publishers

Results (42)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Journal Article

    Borazanci, E.; Schram, A. M.; Garralda, E.; Brana, I.; Vieito Villar, M.; Spreafico, A.; Oliva, M.; Lakhani, N. J.; Hoffman, K.; Hallett, R. M.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Natural history and characteristics of ERBB2-mutated hormone receptor-positive metastatic breast cancer: A multi-institutional retrospective case-control study from AACR Project GENIE
    Journal Article

    LeNoue-Newton, M. L.; Chen, S. C.; Stricker, T.; Hyman, D. M.; Blauvelt, N.; Bedard, P. L.; Meric-Bernstam, F.; Punglia, R. S.; Schrag, D.; Lepisto, E. M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • The context-specific role of germline pathogenicity in tumorigenesis
    Journal Article

    Srinivasan, P.; Bandlamudi, C.; Jonsson, P.; Kemel, Y.; Chavan, S. S.; Richards, A. L.; Penson, A. V.; Bielski, C. M.; Fong, C.; Syed, A.; more...
    Nature Genetics (2021)

    Fulltext@MSK | Save
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: An intra-patient comparative analysis
    Journal Article

    Italiano, A.; Nanda, S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U.; Vassal, G.; Kummar, S.; van Tilburg, C. M.; Hong, D. S.; Laetsch, T. W.; more...
    Cancers (2020)

    Fulltext@MSK | Save
  • Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
    Journal Article

    Oaknin, A.; Friedman, C. F.; Roman, L. D.; D'Souza, A.; Brana, I.; Bidard, F. C.; Goldman, J.; Alvarez, E. A.; Boni, V.; ElNaggar, A. C.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • MEK inhibitor-associated central retinal vein occlusion associated with hyperhomocysteinemia and MTHFR variants
    Journal Article

    Francis, J. H.; Diamond, E. L.; Chi, P.; Jaben, K.; Hyman, D. M.; Abramson, D. H.
    Ocular Oncology and Pathology (2020)

    Fulltext@MSK | Save
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save